|Videos|April 8, 2022
Residual Cardiovascular Risk
Ian Riddock, MD, describes residual cardiovascular risk, both with and without the use of statin therapies.
Advertisement
Episodes in this series
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol
2
SYNCHRONIZE-1 Through a Hepatologist's Lens: Liver Fat Reduction, Visceral Fat, and What Comes Next
3
Beyond GLP-1: The Biological Case for Dual Incretin Therapy in MASH
4
Stem Cell Transplant Outperforms DMTs in Drug-Resistant Relapsing MS
5